Dose Linearity Testing of Intravenous Ofloxacin, a Novel Gyrase Inhibitor
- 1 January 1988
- journal article
- research article
- Published by S. Karger AG in Chemotherapy
- Vol. 34 (3) , 170-177
- https://doi.org/10.1159/000238567
Abstract
After intravenous bolus injection of single doses of 25, 50, 75 and 100 mg of ofloxacin (HOE 280) to 34 healthy male volunteers, concentrations of unchanged drug were estimated at various times in serum and urine over 32 and 48 h. Ofloxacin concentrations were determined using high-pressure liquid chromatography (HPLC). A linear relationship between dose and Cmax (r = 0.91), AUC0-32 (r = 0.95), AUC.infin. ( r = 0.96) and urinary recovery (r = 0.98) was demonstrated for the doses tested (25-100 mg). The biological half-life (t1/2,.beta.) was determined by fitting a two-compartment open model to the data: t1/2,.beta. was about 4.5-5.1 h (HPLC, mean values) and was not dose-dependent. Clinically relevant high concentrations of unchanged ofloxacin were detected in urine after the lowest dose (25 mg) for about 24 h, and after the highest dose (100 g) for at least 36 h. General tolerance was good. A slight transient drop in blood pressure was seen after 25 mg in one case; in another, local venous irritation and later restlessness were observed after 75 mg. No specific countermeasures, except for a saline injection into the vein, were needed. All volunteers completed the study as planned.This publication has 6 references indexed in Scilit:
- MULTIPLE-DOSE PHARMACOKINETICS OF OFLOXACIN, A NEW BROAD-SPECTRUM ANTIMICROBIAL AGENT1986
- Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patientsInfection, 1986
- Klinische Pharmakologie von Ofloxacin: Ein neues Chemotherapeutikum aus der Reihe der GyrasehemmerInfection, 1986
- Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigsAntimicrobial Agents and Chemotherapy, 1985
- DOSE LINEARITY AND OTHER PHARMACOKINETICS OF OFLOXACIN - A NEW, BROAD-SPECTRUM ANTIMICROBIAL AGENT1985
- Comparative Evaluation of Recently Developed Quinolone Compounds – with a Note on the Frequency of Resistant MutantsChemotherapy, 1985